About

Pattern Bioscience specializes in the rapid identification of bacterial infections and their antibiotic resistance profiles. The company uses advanced digital technology that combines single-cell analysis with artificial intelligence to provide results for identification and antibiotic susceptibility testing in just four hours, a significant reduction from traditional methods that can take days. Its primary customers are hospitals and healthcare providers, including lab directors and infection prevention specialists. Unlike competitors, Pattern Bioscience focuses on delivering faster and more accurate diagnostics, which helps reduce unnecessary antibiotic prescriptions and addresses the global health issue of antibiotic resistance. The company's goal is to improve patient outcomes and combat antibiotic misuse in healthcare settings.

Simplify's Take

What believers are saying

• Raised $28.7 million in Series C funding to accelerate platform development.
• Growing demand for rapid diagnostics due to COVID-19 boosts market potential.
• AI integration in healthcare diagnostics offers significant growth opportunities.

What critics are saying

• Emerging competition in rapid diagnostic technologies threatens market share.
• Potential delays in regulatory approvals could impact market entry.
• Reliance on external funding poses risks if future rounds fall short.

What makes Pattern Bioscience unique

• Pattern Bioscience uses patented phenotypic single-cell technology for pathogen identification.
• Their Digital CultureTM technology offers comprehensive diagnosis without traditional culture steps.
• AI pattern recognition enables rapid ID/AST results in just four hours.

Help us improve and share your feedback! Did you find this helpful?

YesNo